Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. reported a 30% increase in total revenue for 2024, driven by a significant rise in domestic sales of its core product, TUOYI (toripalimab). The company also achieved a 44% reduction in losses due to cost control measures and successful clinical trials. Notably, toripalimab has been approved in the U.S. and Singapore for treating nasopharyngeal carcinoma, marking a significant milestone in its international expansion. These developments underscore the company’s strategic focus on unmet medical needs and its commitment to advancing innovative therapies globally.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a Chinese biopharmaceutical company focused on the discovery, research, development, and commercialization of innovative therapies and drugs. The company operates in various therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases. Its product portfolio includes monoclonal antibodies, small molecule drugs, and other advanced drug modalities.
YTD Price Performance: 20.55%
Average Trading Volume: 1,550,382
Technical Sentiment Signal: Hold
Current Market Cap: HK$26.82B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.